Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
|Videos|June 15, 2022
A US-Based, Injectables-Focused CDMO with Available Capacity and End-to-End Capabilities
Author(s)August Bioservices
Ryan Downey, Director of Customer Operations, outlines August Bioservices’ capabilities for its customers and what it means to work with them.
- They focus on sterile injectables in multiple container sizes from vials to syringes to flexible IV bags— coupled with an analytical services department.
- The current CDMO market is constrained for those who need the capacity to start their innovative work, which is where August Bioservices comes in.
- With robust tools and a strong team, they can solve difficult challenges with formulation, commercial configuration, the timing of a project, and analytical characterizations.
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.